



### Cardiovascular Standing Committee Fall 2019 Measure Evaluation In-Person Meeting

---

February 6, 2020

#### Participant Instructions

For those attending virtually, please follow the instructions below 15 minutes prior to the scheduled start time.

1. Direct your web browser to the following URL:  
<https://core.callinfo.com/callme/?ap=8007682983&ac=7225131&role=p&mode=ad>
2. Enter your name in the fields provided and click “Join Web Meeting”
3. On your phone, please dial **800-768-2983** and use access code **7225131**

#### Meeting Objectives

- Overview of the evaluation process
- Consideration of candidate measures and voting

<b>8:30 am</b>	<b>Welcome</b> <i>Mary George, MD, MSPH, FACS, FAHA, Co-chair</i> <i>Thomas Kottke, MD, MSPH, Co-chair</i> <i>Amy Moyer, MS, PMP, NQF Director</i>
<b>8:40 am</b>	<b>Introductions, Disclosures of Interest, and Cardiovascular Measures Under Review</b> <i>Kathleen Giblin, RN, NQF Senior Vice President</i> <i>Janaki Panchal, MSPH, NQF Manager</i>
<b>8:50 am</b>	<b>Overview of Evaluation Process</b> <i>Ameera Chaudhry, MS, NQF Analyst</i>
<b>9:00 am</b>	<b>Consideration of Candidate Measures</b> <i>Mary George</i> <i>Thomas Kottke</i> <i>Amy Moyer</i> <ul style="list-style-type: none"><li>• <b>0018</b> Controlling High Blood Pressure</li></ul>
<b>10:30 am</b>	<b>Break</b>
<b>10:45 am</b>	<b>Consideration of Candidate Measures (continued)</b> <ul style="list-style-type: none"><li>• <b>0071</b> Persistence of Beta-Blocker Treatment After a Heart Attack</li></ul>
<b>11:45 am</b>	<b>Break for Lunch</b>

- 12:30 pm**      **Consideration of Candidate Measures (continued)**
- **0670** Cardiac stress imaging not meeting appropriate use criteria - Preoperative evaluation in low risk surgery patients
  - **0671** Cardiac stress imaging not meeting appropriate use criteria - Routine testing after percutaneous coronary intervention
  - **0672** Cardiac stress imaging not meeting appropriate use criteria - Testing in asymptomatic, low risk patients
- 2:30 pm**      **Break**
- 2:45 pm**      **Consideration of Candidate Measures (continued)**
- **0965** Discharge Medications (ACE ARB and beta blockers) in Eligible ICD CRT-D Implant Patients
  - **3534** 30-Day All-cause Risk Standardized Mortality Odds Ratio following Transcatheter Aortic Valve Replacement (TAVR)
- 4:45 pm**      **NQF Member and Public Comment**  
*Ameera Chaudhry*
- 4:55 pm**      **Next Steps**  
*Ameera Chaudhry*
- 5:00 pm**      **Adjourn**